Abstract: Described herein is the finding that increasing the frequency of Zscan4 activation in mouse ES cells not only enhances, but also maintains their developmental potency in long-term cell culture. As the potency increases, even a whole animal can be produced from a single ES cell injected into a 4N blastocyst at an unexpectedly high success rate. The studies disclosed herein indicate that ES cells acquire higher potency by going through the transient Zscan4 activation state more frequently than the regular state. Particularly disclosed herein is the finding that the constitutive presence of Zscan4-ERT2, even in the absence of its usual activator tamoxifen, can increase the frequency of endogenous Zscan4 activation in ES cells, resulting in the increase of developmental potency of the ES cells. Accordingly, provided herein are Zscan4-ERT2 fusion proteins and nucleic acid molecules and vectors encoding Zscan4-ERT2 fusion proteins.
Type:
Grant
Filed:
May 7, 2019
Date of Patent:
November 30, 2021
Assignees:
Elixirgen, LLC, The U.S. of America, as Represented by the Secretary for the
Department of Health and Human Service
Abstract: Described herein is the finding that increasing the frequency of Zscan4 activation in mouse ES cells not only enhances, but also maintains their developmental potency in long-term cell culture. As the potency increases, even a whole animal can be produced from a single ES cell injected into a 4N blastocyst at an unexpectedly high success rate. The studies disclosed herein indicate that ES cells acquire higher potency by going through the transient Zscan4 activation state more frequently than the regular state. Particularly disclosed herein is the finding that the constitutive presence of Zscan4-ERT2, even in the absence of its usual activator tamoxifen, can increase the frequency of endogenous Zscan4 activation in ES cells, resulting in the increase of developmental potency of the ES cells. Accordingly, provided herein are Zscan4-ERT2 fusion proteins and nucleic acid molecules and vectors encoding Zscan4-ERT2 fusion proteins.
Type:
Application
Filed:
May 7, 2019
Publication date:
October 31, 2019
Applicants:
Elixirgen, LLC, The U.S. of America, as Represented by the Secretary for the Department of Health and Human Service
Abstract: Methods are disclosed herein for treating glaucoma in a subject. In some embodiments, the methods increase retinal ganglion cell survival. The disclosed method use exosomes and/or miRNA.
Type:
Application
Filed:
January 24, 2019
Publication date:
July 25, 2019
Applicant:
THE U.S. OF AMERICA, as represented by the Secretary, Department of Health and Human Services
Inventors:
Stanislav Ivanovich Tomarev, Benjamin Frank John Martin Mead
Abstract: The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases.
Type:
Application
Filed:
December 15, 2008
Publication date:
June 9, 2011
Applicants:
University of Pittsburgh - Of the Commonwealth System of Higher Education, The U.S.of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
Patrick M. Moore, Yuan Chang, Huichen Feng, Christopher Brian Buck, Diana V. Pastrana
Abstract: Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.
Type:
Application
Filed:
May 19, 2010
Publication date:
November 4, 2010
Applicant:
The U.S. of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Patrick Hwu, Rejean LaPointe, Steven A. Rosenberg, Maria Parkhurst
Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
Type:
Application
Filed:
May 27, 2003
Publication date:
January 22, 2004
Applicant:
U.S. of America, represented by the Secretary, Department of Health and Human Services.
Inventors:
Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman